Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMVT Immunovant, Inc.

Market Closed 09-04 16:00:00 EDT

39.25

+0.13

+0.33%

盘后39.25

+0.000.00%

19:30 EDT

High39.73	Low38.73	Vol765.74K
Open39.44	D1 Closing39.12	Amplitude2.56%
Mkt Cap8.10B	Tradable Cap3.52B	Total Shares206.40M
T/O30.08M	T/O Rate0.85%	Tradable Shares89.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMVT","market":"US","secType":"STK","nameCN":"Immunovant, Inc.","latestPrice":39.25,"timestamp":1788552000000,"preClose":39.12,"halted":0,"volume":765742,"hourTrading":{"tag":"盘后","latestPrice":39.25,"preClose":39.25,"latestTime":"19:30 EDT","volume":68306,"amount":2680867.5,"timestamp":1788564602414,"change":0,"changeRate":0,"amplitude":0.006369},"delay":0,"changeRate":0.0033231083844581432,"floatShares":89566827,"shares":206402338,"eps":-2.817767,"marketStatus":"Market Closed","change":0.13,"latestTime":"09-04 16:00:00 EDT","open":39.44,"high":39.73,"low":38.73,"amount":30078044.057652,"amplitude":0.025562,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.817767,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":39.12,"preHourTrading":{"tag":"盘前","latestPrice":39.44,"preClose":39.12,"latestTime":"09:29 EDT","volume":1912,"amount":75348.24896,"timestamp":1788528599999,"change":0.32,"changeRate":0.00818,"amplitude":0.019826},"postHourTrading":{"tag":"盘后","latestPrice":39.25,"preClose":39.25,"latestTime":"19:30 EDT","volume":68306,"amount":2680867.5,"timestamp":1788564602414,"change":0,"changeRate":0,"amplitude":0.006369},"volumeRatio":0.5777967389596925,"impliedVol":0.6907,"impliedVolPercentile":0.7579},"requestUrl":"/m/hq/s/IMVT/wiki","defaultTab":"wiki","newsList":[{"id":"2664049898","title":"Immunovant Holds Annual Stockholder Meeting with 96% Shares Represented","url":"https://stock-news.laohu8.com/highlight/detail?id=2664049898","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664049898?lang=en_us&edition=fundamental","pubTime":"2026-09-04 05:06","pubTimestamp":1788469582,"startTime":"0","endTime":"0","summary":"Immunovant holds annual stockholder meeting with 96% shares representedImmunovant held its annual shareholder meeting on Sept. 2, 2026.Shareholders backed the selection of Ernst & Young as independent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL364hlT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4585","BK4139","BK4007","PTH","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664125867","title":"Roivant Sciences President, Immunovant CEO Eric Venker Disposes of Common Shares Worth $7.15 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664125867","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664125867?lang=en_us&edition=fundamental","pubTime":"2026-09-02 09:01","pubTimestamp":1788310876,"startTime":"0","endTime":"0","summary":"Roivant Sciences President, Immunovant CEO Eric Venker disposes of common shares worth $7.15 millionRoivant Sciences President and Immunovant CEO Eric Venker cut his stake to 1,599,154 common shares o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL1wcvb5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4007","BK4139","PTH","BK4588","ROIV","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013728","title":"Immunovant Director Atul Pande Disposes of 1,500 Common Shares Worth $64,905","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013728","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663013728?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:29","pubTimestamp":1787948961,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande disposes of 1,500 common shares worth $64,905Immunovant director Atul Pande exercised stock options for 1,500 shares at $8.43 on Aug. 28, 2026.He sold 1,500 shares at $4","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLRTwYM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","PTH","ROIV","BK4007","BK4139","IMVT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662208957","title":"Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2662208957","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662208957?lang=en_us&edition=fundamental","pubTime":"2026-08-25 01:16","pubTimestamp":1787591795,"startTime":"0","endTime":"0","summary":"Immunovant  has broad diversification with encouraging updates but faces balanced risk/reward profile after its stock's recent rally, UBS said in a note email Monday.The company's recent updates have moved UBS analysts to factor in more potential disease indications for the drug candidate INVT-1402, according to the note. The analysts updated their forecast for 2035 revenue to $3.2 billion from $1.9 billion previously, taking into account difficult-to-treat rheumatoid arthritis, as well as upcoming datasets such as cutaneous lupus erythematosus and Sjogren's disease.The company's stock price recently rose following positive clinical data in difficult-to-treat rheumatoid arthritis, which could have a favorable readthrough to other indications, the analysts said.However, the analysts said they remain \"on the sidelines\" until the phase 2 rheumatoid arthritis trial results, expected in H2, which may be mixed, but potentially could lead to clearer positive catalysts in 2027.Clinical trial r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IMVT","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661744472","title":"UBS Adjusts Immunovant Price Target to $40 From $24, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2661744472","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661744472?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:09","pubTimestamp":1787580587,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT) has an average rating of buy and mean price target of $46.77, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4139","IMVT","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279085","title":"UBS Remains a Hold on Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279085","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279085?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:45","pubTimestamp":1787575538,"startTime":"0","endTime":"0","summary":"UBS analyst maintained a Hold rating on Immunovant today and set a price target of $40.00. Currently, the analyst consensus on Immunovant is a Stro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ubs-remains-a-hold-on-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ubs-remains-a-hold-on-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","IMVT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659241311","title":"Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype","url":"https://stock-news.laohu8.com/highlight/detail?id=2659241311","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659241311?lang=en_us&edition=fundamental","pubTime":"2026-08-15 05:21","pubTimestamp":1786742465,"startTime":"0","endTime":"0","summary":"Immunovant, Inc. reported first‑quarter 2026 results showing a wider net loss of US$153.22 million, or US$0.75 per share, compared with a net loss of US$120.61 million, or US$0.71 per share, a year earlier.\nAlongside these results, CEO Matthew Gline highlighted multiple upcoming pivotal data readouts and potential launches across autoimmune indications, supported by a significant upfront payment from Moderna and ongoing litigation–related cash inflows that could reshape the company’s funding...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/why-immunovant-imvt-is-up-52-after-wider-q1-loss-moderna-cas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/why-immunovant-imvt-is-up-52-after-wider-q1-loss-moderna-cas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","IMVT","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657632405","title":"Immunovant, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632405","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657632405?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:32","pubTimestamp":1786023121,"startTime":"0","endTime":"0","summary":"Immunovant, Inc. reports results for the quarter ended June 30 - Earnings SummaryImmunovant, Inc.IMVT.OQreported a quarterly adjusted loss of 75 cents per share for the quarter ended June 30, lower th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431VO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","BK4588","PTH","ROIV","IMVT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657563963","title":"Immunovant Fiscal Q1 2027 Results: IMVT-1402 Spending Widens Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657563963","media":"TradingKey","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657563963?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:06","pubTimestamp":1786018009,"startTime":"0","endTime":"0","summary":"Immunovant’s fiscal Q1 2027 results showed a GAAP net loss of $153.2 million, compared with $120.6 million a year earlier, while loss per share widened to $0.75 from $0.71. R&D expense rose about 41% to $142.6 million as IMVT-1402 clinical trials and contract manufacturing expanded, partly offset by lower batoclimab spending and a 32% decline in G&A expense. The company ended June 2026 with $797.8 million in cash and said its runway extends to a potential IMVT-1402 launch in Graves’ disease under the current operating plan.","market":"sh","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock3.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262083546-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IMVT","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657169636","title":"Immunovant reports Q2 EPS (75c), consensus (61c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657169636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657169636?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:01","pubTimestamp":1786017718,"startTime":"0","endTime":"0","summary":"The company said, “Immunovant’s (IMVT) development plans for IMVT-1402 remain on track across all six announced indications. The Company expects to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunovant-reports-q2-eps-75c-consensus-61c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunovant-reports-q2-eps-75c-consensus-61c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMVT","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657335626","title":"Immunovant FY27 Q1 Net Loss Widens 27% to $153.2 Million; R&D Expenses Rise 40.9% to $142.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657335626","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657335626?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:20","pubTimestamp":1786015233,"startTime":"0","endTime":"0","summary":"Immunovant FY27 Q1 net loss widens 27% to $153.2 million; R&D expenses rise 40.9% to $142.6 millionImmunovant posted a wider net loss of USD 153.2 million, or USD 0.75 a share, for the quarter ended J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLnH5Br:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","PTH","ROIV","BK4007","BK4139","IMVT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633815","title":"Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633815","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633815?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:17","pubTimestamp":1786015029,"startTime":"0","endTime":"0","summary":"Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680710","title":"Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680710","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680710?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:01","pubTimestamp":1786014087,"startTime":"0","endTime":"0","summary":"Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 5.63 percent decrease over losses of $(0.71) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60986784/immunovant-q1-eps-0-75-misses-0-61-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657981638","title":"Immunovant Q1 Net Income USD -153.224 Million Vs. IBES Estimate USD -130.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657981638","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657981638?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:01","pubTimestamp":1786014062,"startTime":"0","endTime":"0","summary":"BRIEF-Immunovant Q1 Net Income USD -153.224 Million Vs. IBES Estimate USD -130.2 MillionAug 06 (Reuters) - Immunovant Q1 operating expenses USD 160.323 million.Q1 basic EPS USD -0.75","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX535BZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMVT","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633904","title":"Immunovant, - Cash and Cash Equivalents Total $797.80 Mln as of June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633904?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX535BZQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMVT","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656552336","title":"J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656552336","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656552336?lang=en_us&edition=fundamental","pubTime":"2026-08-04 22:21","pubTimestamp":1785853299,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Brian Cheng maintained a Buy rating on Immunovant today and set a price target of $50.00. Cheng covers the Healthcare sector, f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-buy-rating-for-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-buy-rating-for-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168165416","title":"Earning Preview: Immunovant, Inc. Q2 revenue is expected to be flat, and institutional views are predominantly bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1168165416","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168165416?lang=en_us&edition=fundamental","pubTime":"2026-07-31 09:15","pubTimestamp":1785460503,"startTime":"0","endTime":"0","summary":"Abstract Immunovant, Inc. will report quarterly results on August 06, 2026 Pre-Market; this preview summarizes expected revenue, profitability, EPS trajectory, and institutional sentiment for the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Immunovant, Inc. Q2 revenue is expected to be flat, and institutional views are predominantly bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655845522","title":"Roivant President, Immunovant CEO Eric Venker Sells USD 6.99 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2655845522","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655845522?lang=en_us&edition=fundamental","pubTime":"2026-07-30 09:00","pubTimestamp":1785373245,"startTime":"0","endTime":"0","summary":"Roivant President, Immunovant CEO Eric Venker sells USD 6.99 million in common sharesRoivant Sciences President and Immunovant CEO Eric Venker sold 200,000 common shares on July 27 at a weighted avera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL6q3Bq2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","ROIV","IMVT","PTH","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654619030","title":"Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $59,700","url":"https://stock-news.laohu8.com/highlight/detail?id=2654619030","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654619030?lang=en_us&edition=fundamental","pubTime":"2026-07-25 05:59","pubTimestamp":1784930385,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande disposes of 1,500 common shares for $59,700Immunovant director Atul Pande sold 1,500 shares on July 24, 2026 at USD 39.8.The sale followed the exercise of stock options ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDLbGPzpM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","IMVT","BK4585","BK4588","BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653490775","title":"Immunovant Updates Financial Calendar with First-quarter Results Release and Business Update Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2653490775","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653490775?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:26","pubTimestamp":1784838369,"startTime":"0","endTime":"0","summary":"Immunovant updates financial calendar with first-quarter results release and business update callImmunovant to report fiscal Q1 results for the period ended June 30, 2026 on Aug. 6, 2026, before the m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL78ZZLp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","BCDF","IMVT","SG9999014039.USD","BK4112","BK4588","BK4585","PTH","SG9999014013.SGD","BK4007","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4139","LU2210149790.SGD","SG9999014021.USD","LU0314104364.USD","NDAQ","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunovant.com","stockEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.2617},{"period":"6month","weight":0.4722},{"period":"1year","weight":1.4349},{"period":"ytd","weight":0.5441}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.081969},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.118937},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.068553},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.009383},{"month":5,"riseRate":0.428571,"avgChangeRate":0.091771},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.03669},{"month":7,"riseRate":0.625,"avgChangeRate":0.035685},{"month":8,"riseRate":0.625,"avgChangeRate":0.07742},{"month":9,"riseRate":0.75,"avgChangeRate":0.10091},{"month":10,"riseRate":0.714286,"avgChangeRate":0.22916},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058678},{"month":12,"riseRate":0.714286,"avgChangeRate":0.132246}],"exchange":"NASDAQ","name":"Immunovant, Inc.","nameEN":"Immunovant, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunovant, Inc.,IMVT,Immunovant, Inc.股票,Immunovant, Inc.股票老虎,Immunovant, Inc.股票老虎国际,Immunovant, Inc.行情,Immunovant, Inc.股票行情,Immunovant, Inc.股价,Immunovant, Inc.股市,Immunovant, Inc.股票价格,Immunovant, Inc.股票交易,Immunovant, Inc.股票购买,Immunovant, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction